Monopar Therapeutics Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Monopar Therapeutics Inc. (MNPR) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- Monopar Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.43M, a 11.64% increase year-over-year.
- Monopar Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.69M, a 24.94% increase year-over-year.
- Monopar Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.10M, a 452.03% increase year-over-year.
- Monopar Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.28M, a 282.65% increase year-over-year.
- Monopar Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $4.84M, a 324.08% increase from fiscal 2024.
- Monopar Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.14M, a 39.89% decline from fiscal 2023.
- Monopar Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.90M, a 15.63% increase from fiscal 2022.
- Monopar Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.64M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.43M 10-Q · filed 2026-08-12 | $3.12M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $1.69M 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $4.84M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $1.10M 10-Q · filed 2025-11-13 | $2.38M derived: sum of 2 quarters · filed 2026-08-12 | $3.73M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $1.28M 10-Q · filed 2026-08-12 | $2.63M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $1.36M 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $1.14M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | $199.12K 10-Q · filed 2025-11-13 | $533.51K derived: sum of 2 quarters · filed 2025-11-13 | $862.17K derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $334.39K 10-Q · filed 2025-11-13 | $663.05K derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $328.66K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $1.90M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $474.14K 10-Q · filed 2024-11-08 | $947.43K derived: sum of 2 quarters · filed 2024-11-08 | $1.42M derived: sum of 3 quarters · filed 2024-11-08 | |
| 2023-06-30 | $473.30K 10-Q · filed 2024-11-08 | $949.50K derived: sum of 2 quarters · filed 2024-11-08 | ||
| 2023-03-31 | $476.21K 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $1.64M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $390.74K 10-Q · filed 2023-11-09 | $748.03K derived: sum of 2 quarters · filed 2023-11-09 | $1.25M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $357.29K 10-Q · filed 2023-11-09 | $857.11K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $499.81K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |